ID   POL_FOAMV               Reviewed;        1143 AA.
AC   P14350; O12528; O12817; Q76U32; Q98835;
DT   01-JAN-1990, integrated into UniProtKB/Swiss-Prot.
DT   11-JUL-2006, sequence version 2.
DT   07-APR-2021, entry version 161.
DE   RecName: Full=Pro-Pol polyprotein;
DE   AltName: Full=Pr125Pol;
DE   Contains:
DE     RecName: Full=Protease/Reverse transcriptase/ribonuclease H;
DE              EC=2.7.7.49;
DE              EC=2.7.7.7;
DE              EC=3.1.26.4;
DE              EC=3.4.23.-;
DE     AltName: Full=p87Pro-RT-RNaseH;
DE   Contains:
DE     RecName: Full=Protease/Reverse transcriptase;
DE              EC=2.7.7.49;
DE              EC=2.7.7.7;
DE              EC=3.4.23.-;
DE     AltName: Full=p65Pro-RT;
DE   Contains:
DE     RecName: Full=Ribonuclease H;
DE              Short=RNase H;
DE              EC=3.1.26.4;
DE   Contains:
DE     RecName: Full=Integrase;
DE              Short=IN;
DE              EC=2.7.7.- {ECO:0000305|PubMed:23872492};
DE              EC=3.1.-.- {ECO:0000305|PubMed:23872492};
DE     AltName: Full=p42In;
GN   Name=pol;
OS   Human spumaretrovirus (SFVcpz(hu)) (Human foamy virus).
OC   Viruses; Riboviria; Pararnavirae; Artverviricota; Revtraviricetes;
OC   Ortervirales; Retroviridae; Spumaretrovirinae; Spumavirus.
OX   NCBI_TaxID=11963;
OH   NCBI_TaxID=9606; Homo sapiens (Human).
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA], AND SEQUENCE REVISION.
RA   Fluegel R.M.;
RL   Submitted (FEB-1995) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RA   Schmidt M., Herchenrder O., Heeney J.L., Rethwilm A.;
RT   "Long terminal repeat U3-length polymorphism of human foamy virus.";
RL   Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 1-742.
RX   PubMed=2451755; DOI=10.1128/jvi.62.5.1590-1597.1988;
RA   Maurer B., Bannert H., Darai G., Fluegel R.M.;
RT   "Analysis of the primary structure of the long terminal repeat and the gag
RT   and pol genes of the human spumaretrovirus.";
RL   J. Virol. 62:1590-1597(1988).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC RNA] OF 741-886.
RX   PubMed=2820721; DOI=10.1002/j.1460-2075.1987.tb02473.x;
RA   Fluegel R.M., Rethwilm A., Maurer B., Darai G.;
RT   "Nucleotide sequence analysis of the env gene and its flanking regions of
RT   the human spumaretrovirus reveals two novel genes.";
RL   EMBO J. 6:2077-2084(1987).
RN   [5]
RP   ACTIVE SITE OF PROTEASE, AND MUTAGENESIS OF ASP-24 AND SER-25.
RX   PubMed=7474150; DOI=10.1128/jvi.69.11.7264-7268.1995;
RA   Konvalinka J., Loechelt M., Zentgraf H., Fluegel R.M., Kraeusslich H.-G.;
RT   "Active foamy virus proteinase is essential for virus infectivity but not
RT   for formation of a Pol polyprotein.";
RL   J. Virol. 69:7264-7268(1995).
RN   [6]
RP   MUTAGENESIS OF PRO-152; PRO-169; PRO-193; ASP-599 AND TYR-672.
RX   PubMed=7544460; DOI=10.1093/nar/23.14.2621;
RA   Kogel D., Aboud M., Fluegel R.M.;
RT   "Mutational analysis of the reverse transcriptase and ribonuclease H
RT   domains of the human foamy virus.";
RL   Nucleic Acids Res. 23:2621-2625(1995).
RN   [7]
RP   CHARACTERIZATION OF POLYPROTEIN.
RX   PubMed=8551561; DOI=10.1128/jvi.70.2.1033-1040.1996;
RA   Loechelt M., Fluegel R.M.;
RT   "The human foamy virus pol gene is expressed as a Pro-Pol polyprotein and
RT   not as a Gag-Pol fusion protein.";
RL   J. Virol. 70:1033-1040(1996).
RN   [8]
RP   PROTEOLYTIC PROCESSING OF POLYPROTEIN.
RX   PubMed=9696869; DOI=10.1128/jvi.72.9.7648-7652.1998;
RA   Pfrepper K.-I., Rackwitz H.R., Schnoelzer M., Heid H., Loechelt M.,
RA   Fluegel R.M.;
RT   "Molecular characterization of proteolytic processing of the Pol proteins
RT   of human foamy virus reveals novel features of the viral protease.";
RL   J. Virol. 72:7648-7652(1998).
RN   [9]
RP   SUBCELLULAR LOCATION.
RC   STRAIN=Isolate HSRV2;
RX   PubMed=11086125; DOI=10.1099/0022-1317-81-12-2941;
RA   Imrich H., Heinkelein M., Herchenroder O., Rethwilm A.;
RT   "Primate foamy virus Pol proteins are imported into the nucleus.";
RL   J. Gen. Virol. 81:2941-2947(2000).
RN   [10]
RP   CHARACTERIZATION OF REVERSE TRANSCRIPTASE.
RX   PubMed=12829852; DOI=10.1128/jvi.77.14.8141-8146.2003;
RA   Delelis O., Saib A., Sonigo P.;
RT   "Biphasic DNA synthesis in spumaviruses.";
RL   J. Virol. 77:8141-8146(2003).
RN   [11]
RP   CHARACTERIZATION OF INTEGRASE.
RX   PubMed=14963145; DOI=10.1128/jvi.78.5.2472-2477.2004;
RA   Juretzek T., Holm T., Gartner K., Kanzler S., Lindemann D.,
RA   Herchenroder O., Picard-Maureau M., Rammling M., Heinkelein M.,
RA   Rethwilm A.;
RT   "Foamy virus integration.";
RL   J. Virol. 78:2472-2477(2004).
RN   [12]
RP   REVIEW.
RX   PubMed=12908768; DOI=10.1007/978-3-642-55701-9_3;
RA   Fluegel R.M., Pfrepper K.-I.;
RT   "Proteolytic processing of foamy virus Gag and Pol proteins.";
RL   Curr. Top. Microbiol. Immunol. 277:63-88(2003).
RN   [13]
RP   REVIEW.
RX   PubMed=15358259; DOI=10.1016/j.mib.2004.06.009;
RA   Delelis O., Lehmann-Che J., Saib A.;
RT   "Foamy viruses-a world apart.";
RL   Curr. Opin. Microbiol. 7:400-406(2004).
RN   [14]
RP   REVIEW (INTEGRASE).
RX   PubMed=23872492; DOI=10.3390/v5071850;
RA   Hossain M.A., Ali M.K., Shin C.G.;
RT   "Structural and functional insights into foamy viral integrase.";
RL   Viruses 5:1850-1866(2013).
CC   -!- FUNCTION: The aspartyl protease activity mediates proteolytic cleavages
CC       of Gag and Pol polyproteins. The reverse transcriptase (RT) activity
CC       converts the viral RNA genome into dsDNA in the cytoplasm, shortly
CC       after virus entry into the cell (early reverse transcription) or after
CC       proviral DNA transcription (late reverse transcription). RT consists of
CC       a DNA polymerase activity that can copy either DNA or RNA templates,
CC       and a ribonuclease H (RNase H) activity that cleaves the RNA strand of
CC       RNA-DNA heteroduplexes in a partially processive 3' to 5' endonucleasic
CC       mode. Conversion of viral genomic RNA into dsDNA requires many steps. A
CC       tRNA-Lys1,2 binds to the primer-binding site (PBS) situated at the 5'-
CC       end of the viral RNA. RT uses the 3' end of the tRNA primer to perform
CC       a short round of RNA-dependent minus-strand DNA synthesis. The reading
CC       proceeds through the U5 region and ends after the repeated (R) region
CC       which is present at both ends of viral RNA. The portion of the RNA-DNA
CC       heteroduplex is digested by the RNase H, resulting in a ssDNA product
CC       attached to the tRNA primer. This ssDNA/tRNA hybridizes with the
CC       identical R region situated at the 3' end of viral RNA. This template
CC       exchange, known as minus-strand DNA strong stop transfer, can be either
CC       intra- or intermolecular. RT uses the 3' end of this newly synthesized
CC       short ssDNA to perform the RNA-dependent minus-strand DNA synthesis of
CC       the whole template. RNase H digests the RNA template except for a
CC       polypurine tract (PPT) situated at the 5'-end and near the center of
CC       the genome. It is not clear if both polymerase and RNase H activities
CC       are simultaneous. RNase H probably can proceed both in a polymerase-
CC       dependent (RNA cut into small fragments by the same RT performing DNA
CC       synthesis) and a polymerase-independent mode (cleavage of remaining RNA
CC       fragments by free RTs). Secondly, RT performs DNA-directed plus-strand
CC       DNA synthesis using the PPT that has not been removed by RNase H as
CC       primer. PPT and tRNA primers are then removed by RNase H. The 3' and 5'
CC       ssDNA PBS regions hybridize to form a circular dsDNA intermediate.
CC       Strand displacement synthesis by RT to the PBS and PPT ends produces a
CC       blunt ended, linear dsDNA copy of the viral genome that includes long
CC       terminal repeats (LTRs) at both ends (By similarity). {ECO:0000250}.
CC   -!- FUNCTION: Integrase catalyzes viral DNA integration into the host
CC       chromosome, by performing a series of DNA cutting and joining
CC       reactions. This enzyme activity takes place after virion entry into a
CC       cell and reverse transcription of the RNA genome in dsDNA. The first
CC       step in the integration process is 3' processing. This step requires a
CC       complex comprising at least the viral genome, matrix protein, and
CC       integrase. This complex is called the pre-integration complex (PIC).
CC       The integrase protein removes 2 nucleotides from the 3' end of the
CC       viral DNA right (U5) end, leaving the left (U3) intact. In the second
CC       step, the PIC enters cell nucleus. This process is mediated through the
CC       integrase and allows the virus to infect both dividing (nuclear
CC       membrane disassembled) and G1/S-arrested cells (active translocation),
CC       but with no viral gene expression in the latter. In the third step,
CC       termed strand transfer, the integrase protein joins the previously
CC       processed 3' ends to the 5' ends of strands of target cellular DNA at
CC       the site of integration. It is however not clear how integration then
CC       proceeds to resolve the asymmetrical cleavage of viral DNA (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Endonucleolytic cleavage to 5'-phosphomonoester.; EC=3.1.26.4;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU00408};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2'-deoxyribonucleoside 5'-triphosphate + DNA(n) =
CC         diphosphate + DNA(n+1); Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:11130,
CC         Rhea:RHEA-COMP:11131, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560,
CC         ChEBI:CHEBI:83828; EC=2.7.7.49; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00405};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2'-deoxyribonucleoside 5'-triphosphate + DNA(n) =
CC         diphosphate + DNA(n+1); Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:11130,
CC         Rhea:RHEA-COMP:11131, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560,
CC         ChEBI:CHEBI:83828; EC=2.7.7.7; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00405};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for reverse transcriptase polymerase
CC       activity. {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Binds 2 magnesium ions for ribonuclease H (RNase H) activity.
CC       Substrate-binding is a precondition for magnesium binding.
CC       {ECO:0000250};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Note=Magnesium ions are required for integrase activity. Binds at least
CC       1, maybe 2 magnesium ions. {ECO:0000250};
CC   -!- SUBUNIT: The protease is a homodimer, whose active site consists of two
CC       apposed aspartic acid residues. {ECO:0000255|PROSITE-ProRule:PRU00863}.
CC   -!- INTERACTION:
CC       PRO_0000245446; PRO_0000245446 [P14350]: pol; NbExp=6; IntAct=EBI-16013918, EBI-16013918;
CC   -!- SUBCELLULAR LOCATION: [Integrase]: Virion {ECO:0000305}. Host nucleus.
CC       Host cytoplasm {ECO:0000305}. Note=Nuclear at initial phase,
CC       cytoplasmic at assembly. {ECO:0000305}.
CC   -!- SUBCELLULAR LOCATION: [Protease/Reverse transcriptase/ribonuclease H]:
CC       Host nucleus {ECO:0000250}. Host cytoplasm {ECO:0000305}. Note=Nuclear
CC       at initial phase, cytoplasmic at assembly. {ECO:0000305}.
CC   -!- DOMAIN: The reverse transcriptase/ribonuclease H (RT) is structured in
CC       five subdomains: finger, palm, thumb, connection and RNase H. Within
CC       the palm subdomain, the 'primer grip' region is thought to be involved
CC       in the positioning of the primer terminus for accommodating the
CC       incoming nucleotide. The RNase H domain stabilizes the association of
CC       RT with primer-template (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: Integrase core domain contains the D-x(n)-D-x(35)-E motif,
CC       named for the phylogenetically conserved glutamic acid and aspartic
CC       acid residues and the invariant 35 amino acid spacing between the
CC       second and third acidic residues. Each acidic residue of the D,D(35)E
CC       motif is independently essential for the 3'-processing and strand
CC       transfer activities of purified integrase protein (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Specific enzymatic cleavages in vivo by viral protease yield
CC       mature proteins. The protease is not cleaved off from Pol. Since
CC       cleavage efficiency is not optimal for all sites, long and active
CC       p65Pro-RT, p87Pro-RT-RNaseH and even some Pr125Pol are detected in
CC       infected cells. {ECO:0000269|PubMed:9696869}.
CC   -!- MISCELLANEOUS: The reverse transcriptase is an error-prone enzyme that
CC       lacks a proof-reading function. High mutations rate is a direct
CC       consequence of this characteristic. RT also displays frequent template
CC       switching leading to high recombination rate. Recombination mostly
CC       occurs between homologous regions of the two copackaged RNA genomes. If
CC       these two RNA molecules derive from different viral strains, reverse
CC       transcription will give rise to highly recombinated proviral DNAs.
CC   -!- MISCELLANEOUS: Foamy viruses are distinct from other retroviruses in
CC       many respects. Their protease is active as an uncleaved Pro-Pol
CC       protein. Mature particles do not include the usual processed retroviral
CC       structural protein (MA, CA and NC), but instead contain two large Gag
CC       proteins. Their functional nucleic acid appears to be either RNA or
CC       dsDNA (up to 20% of extracellular particles), because they probably
CC       proceed either to an early (before integration) or late reverse
CC       transcription (after assembly). Foamy viruses have the ability to
CC       retrotranspose intracellularly with high efficiency. They bud
CC       predominantly into the endoplasmic reticulum (ER) and occasionally at
CC       the plasma membrane. Budding requires the presence of Env proteins.
CC       Most viral particles probably remain within the infected cell.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAA46122.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=AAA66556.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U21247; AAB48112.1; -; Genomic_RNA.
DR   EMBL; Y07723; CAA68997.1; -; Genomic_DNA.
DR   EMBL; Y07724; CAA68999.1; -; Genomic_DNA.
DR   EMBL; Y07725; CAA69003.1; -; Genomic_DNA.
DR   EMBL; M19427; AAA66556.1; ALT_INIT; Genomic_RNA.
DR   EMBL; M54978; AAA46122.1; ALT_FRAME; Genomic_RNA.
DR   PDB; 2LSN; NMR; -; A=591-751.
DR   PDB; 2X6N; X-ray; 2.06 A; A/B/C/D/E/F=861-1060.
DR   PDB; 2X6S; X-ray; 2.29 A; A/B/C/D/E/F=861-1060.
DR   PDB; 2X74; X-ray; 2.34 A; A/B/C/D/E/F=861-1060.
DR   PDB; 2X78; X-ray; 2.00 A; A/B/C=861-1060.
DR   PDB; 3DLR; X-ray; 2.20 A; A=859-1058.
DR   PDB; 3L2Q; X-ray; 3.25 A; A/B=752-1143.
DR   PDB; 3L2R; X-ray; 2.88 A; A/B=752-1143.
DR   PDB; 3L2U; X-ray; 3.15 A; A/B=752-1143.
DR   PDB; 3L2V; X-ray; 3.20 A; A/B=752-1143.
DR   PDB; 3L2W; X-ray; 3.20 A; A/B=752-1143.
DR   PDB; 3OS0; X-ray; 2.81 A; A/B=752-1143.
DR   PDB; 3OS1; X-ray; 2.97 A; A/B=752-1143.
DR   PDB; 3OS2; X-ray; 3.32 A; A/B=752-1143.
DR   PDB; 3OY9; X-ray; 2.95 A; A/B=752-1143.
DR   PDB; 3OYA; X-ray; 2.85 A; A/B=752-1143.
DR   PDB; 3OYB; X-ray; 2.54 A; A/B=752-1143.
DR   PDB; 3OYC; X-ray; 2.66 A; A/B=752-1143.
DR   PDB; 3OYD; X-ray; 2.54 A; A/B=752-1143.
DR   PDB; 3OYE; X-ray; 2.74 A; A/B=752-1143.
DR   PDB; 3OYF; X-ray; 2.51 A; A/B=752-1143.
DR   PDB; 3OYG; X-ray; 2.56 A; A/B=752-1143.
DR   PDB; 3OYH; X-ray; 2.74 A; A/B=752-1143.
DR   PDB; 3OYI; X-ray; 2.72 A; A/B=752-1143.
DR   PDB; 3OYJ; X-ray; 2.68 A; A/B=752-1143.
DR   PDB; 3OYK; X-ray; 2.72 A; A/B=752-1143.
DR   PDB; 3OYL; X-ray; 2.54 A; A/B=752-1143.
DR   PDB; 3OYM; X-ray; 2.02 A; A/B=752-1143.
DR   PDB; 3OYN; X-ray; 2.68 A; A/B=752-1143.
DR   PDB; 3S3M; X-ray; 2.49 A; A/B=752-1143.
DR   PDB; 3S3N; X-ray; 2.49 A; A/B=752-1143.
DR   PDB; 3S3O; X-ray; 2.55 A; A/B=752-1143.
DR   PDB; 4BAC; X-ray; 3.26 A; A/B=752-1143.
DR   PDB; 4BDY; X-ray; 2.52 A; A/B=752-1143.
DR   PDB; 4BDZ; X-ray; 2.85 A; A/B=752-1143.
DR   PDB; 4BE0; X-ray; 2.68 A; A/B=752-1143.
DR   PDB; 4BE1; X-ray; 2.71 A; A/B=752-1143.
DR   PDB; 4BE2; X-ray; 2.38 A; A/B=752-1143.
DR   PDB; 4E7H; X-ray; 2.57 A; A/B=752-1143.
DR   PDB; 4E7I; X-ray; 2.53 A; A/B=752-1143.
DR   PDB; 4E7J; X-ray; 3.15 A; A/B=752-1143.
DR   PDB; 4E7K; X-ray; 3.02 A; A/B=752-1143.
DR   PDB; 4E7L; X-ray; 3.00 A; A/B=752-1143.
DR   PDB; 4IKF; X-ray; 3.40 A; A/B=752-1143.
DR   PDB; 4ZTF; X-ray; 2.70 A; A/B=752-1143.
DR   PDB; 4ZTJ; X-ray; 2.67 A; A/B=752-1143.
DR   PDB; 5FRM; X-ray; 2.58 A; A/B=752-1143.
DR   PDB; 5FRN; X-ray; 2.85 A; A/B=752-1143.
DR   PDB; 5FRO; X-ray; 2.67 A; A/B=752-1143.
DR   PDB; 5MMA; X-ray; 2.55 A; A/B=752-1143.
DR   PDB; 5MMB; X-ray; 2.77 A; A/B=753-1143.
DR   PDB; 5NO1; X-ray; 2.60 A; A/B=754-1143.
DR   PDB; 5UOP; X-ray; 2.85 A; A/B=752-1143.
DR   PDB; 5UOQ; X-ray; 2.61 A; A/B=752-1143.
DR   PDB; 6RNY; EM; 3.90 A; K/L/O/P=754-1143.
DR   PDBsum; 2LSN; -.
DR   PDBsum; 2X6N; -.
DR   PDBsum; 2X6S; -.
DR   PDBsum; 2X74; -.
DR   PDBsum; 2X78; -.
DR   PDBsum; 3DLR; -.
DR   PDBsum; 3L2Q; -.
DR   PDBsum; 3L2R; -.
DR   PDBsum; 3L2U; -.
DR   PDBsum; 3L2V; -.
DR   PDBsum; 3L2W; -.
DR   PDBsum; 3OS0; -.
DR   PDBsum; 3OS1; -.
DR   PDBsum; 3OS2; -.
DR   PDBsum; 3OY9; -.
DR   PDBsum; 3OYA; -.
DR   PDBsum; 3OYB; -.
DR   PDBsum; 3OYC; -.
DR   PDBsum; 3OYD; -.
DR   PDBsum; 3OYE; -.
DR   PDBsum; 3OYF; -.
DR   PDBsum; 3OYG; -.
DR   PDBsum; 3OYH; -.
DR   PDBsum; 3OYI; -.
DR   PDBsum; 3OYJ; -.
DR   PDBsum; 3OYK; -.
DR   PDBsum; 3OYL; -.
DR   PDBsum; 3OYM; -.
DR   PDBsum; 3OYN; -.
DR   PDBsum; 3S3M; -.
DR   PDBsum; 3S3N; -.
DR   PDBsum; 3S3O; -.
DR   PDBsum; 4BAC; -.
DR   PDBsum; 4BDY; -.
DR   PDBsum; 4BDZ; -.
DR   PDBsum; 4BE0; -.
DR   PDBsum; 4BE1; -.
DR   PDBsum; 4BE2; -.
DR   PDBsum; 4E7H; -.
DR   PDBsum; 4E7I; -.
DR   PDBsum; 4E7J; -.
DR   PDBsum; 4E7K; -.
DR   PDBsum; 4E7L; -.
DR   PDBsum; 4IKF; -.
DR   PDBsum; 4ZTF; -.
DR   PDBsum; 4ZTJ; -.
DR   PDBsum; 5FRM; -.
DR   PDBsum; 5FRN; -.
DR   PDBsum; 5FRO; -.
DR   PDBsum; 5MMA; -.
DR   PDBsum; 5MMB; -.
DR   PDBsum; 5NO1; -.
DR   PDBsum; 5UOP; -.
DR   PDBsum; 5UOQ; -.
DR   PDBsum; 6RNY; -.
DR   SMR; P14350; -.
DR   DIP; DIP-58582N; -.
DR   MEROPS; A09.001; -.
DR   PRIDE; P14350; -.
DR   EvolutionaryTrace; P14350; -.
DR   Proteomes; UP000138352; Genome.
DR   Proteomes; UP000165559; Genome.
DR   GO; GO:0030430; C:host cell cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0042025; C:host cell nucleus; IEA:UniProtKB-SubCell.
DR   GO; GO:0019012; C:virion; IEA:UniProtKB-SubCell.
DR   GO; GO:0004190; F:aspartic-type endopeptidase activity; IEA:UniProtKB-KW.
DR   GO; GO:0003887; F:DNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; IEA:UniProtKB-KW.
DR   GO; GO:0004523; F:RNA-DNA hybrid ribonuclease activity; IEA:UniProtKB-EC.
DR   GO; GO:0015074; P:DNA integration; IEA:UniProtKB-KW.
DR   GO; GO:0006310; P:DNA recombination; IEA:UniProtKB-KW.
DR   GO; GO:0075713; P:establishment of integrated proviral latency; IEA:UniProtKB-KW.
DR   GO; GO:0046718; P:viral entry into host cell; IEA:UniProtKB-KW.
DR   GO; GO:0044826; P:viral genome integration into host DNA; IEA:UniProtKB-KW.
DR   GO; GO:0075732; P:viral penetration into host nucleus; IEA:UniProtKB-KW.
DR   Gene3D; 2.40.70.10; -; 1.
DR   Gene3D; 3.30.420.10; -; 2.
DR   Gene3D; 3.30.70.270; -; 2.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR001584; Integrase_cat-core.
DR   InterPro; IPR041588; Integrase_H2C2.
DR   InterPro; IPR021109; Peptidase_aspartic_dom_sf.
DR   InterPro; IPR043128; Rev_trsase/Diguanyl_cyclase.
DR   InterPro; IPR012337; RNaseH-like_sf.
DR   InterPro; IPR002156; RNaseH_domain.
DR   InterPro; IPR036397; RNaseH_sf.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR041577; RT_RNaseH_2.
DR   InterPro; IPR040903; SH3_11.
DR   InterPro; IPR001641; Spumavirus_A9.
DR   Pfam; PF17921; Integrase_H2C2; 1.
DR   Pfam; PF00075; RNase_H; 1.
DR   Pfam; PF17919; RT_RNaseH_2; 1.
DR   Pfam; PF00665; rve; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF18103; SH3_11; 1.
DR   Pfam; PF03539; Spuma_A9PTase; 1.
DR   PRINTS; PR00920; SPUMVIRPTASE.
DR   SUPFAM; SSF53098; SSF53098; 2.
DR   SUPFAM; SSF56672; SSF56672; 1.
DR   PROSITE; PS51531; FV_PR; 1.
DR   PROSITE; PS50994; INTEGRASE; 1.
DR   PROSITE; PS50879; RNASE_H; 1.
DR   PROSITE; PS50878; RT_POL; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Aspartyl protease; DNA integration; DNA recombination;
KW   DNA-directed DNA polymerase; Endonuclease; Host cytoplasm; Host nucleus;
KW   Hydrolase; Magnesium; Metal-binding; Multifunctional enzyme; Nuclease;
KW   Nucleotidyltransferase; Protease; Reference proteome; RNA-binding;
KW   RNA-directed DNA polymerase; Transferase; Viral genome integration;
KW   Viral penetration into host nucleus; Virion; Virus entry into host cell.
FT   CHAIN           1..1143
FT                   /note="Pro-Pol polyprotein"
FT                   /id="PRO_0000125483"
FT   CHAIN           1..751
FT                   /note="Protease/Reverse transcriptase/ribonuclease H"
FT                   /id="PRO_0000245443"
FT   CHAIN           1..596
FT                   /note="Protease/Reverse transcriptase"
FT                   /id="PRO_0000245444"
FT   CHAIN           597..751
FT                   /note="Ribonuclease H"
FT                   /id="PRO_0000245445"
FT   CHAIN           752..1143
FT                   /note="Integrase"
FT                   /id="PRO_0000245446"
FT   DOMAIN          1..143
FT                   /note="Peptidase A9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00863"
FT   DOMAIN          198..363
FT                   /note="Reverse transcriptase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   DOMAIN          590..748
FT                   /note="RNase H"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00408"
FT   DOMAIN          868..1024
FT                   /note="Integrase catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00457"
FT   ACT_SITE        24
FT                   /note="For protease activity"
FT                   /evidence="ECO:0000305|PubMed:7474150"
FT   METAL           252
FT                   /note="Magnesium; catalytic; for reverse transcriptase
FT                   activity"
FT                   /evidence="ECO:0000250"
FT   METAL           314
FT                   /note="Magnesium; catalytic; for reverse transcriptase
FT                   activity"
FT                   /evidence="ECO:0000250"
FT   METAL           315
FT                   /note="Magnesium; catalytic; for reverse transcriptase
FT                   activity"
FT                   /evidence="ECO:0000250"
FT   METAL           599
FT                   /note="Magnesium; catalytic; for RNase H activity"
FT                   /evidence="ECO:0000305"
FT   METAL           646
FT                   /note="Magnesium; catalytic; for RNase H activity"
FT                   /evidence="ECO:0000250"
FT   METAL           669
FT                   /note="Magnesium; catalytic; for RNase H activity"
FT                   /evidence="ECO:0000250"
FT   METAL           740
FT                   /note="Magnesium; catalytic; for RNase H activity"
FT                   /evidence="ECO:0000250"
FT   METAL           874
FT                   /note="Magnesium; catalytic; for integrase activity"
FT                   /evidence="ECO:0000250"
FT   METAL           936
FT                   /note="Magnesium; catalytic; for integrase activity"
FT                   /evidence="ECO:0000250"
FT   SITE            596..597
FT                   /note="Cleavage; by viral protease; partial"
FT   SITE            751..752
FT                   /note="Cleavage; by viral protease"
FT   MUTAGEN         24
FT                   /note="D->A: Complete loss of Gag processing and of Pol
FT                   processing. Particles are non-infectious."
FT                   /evidence="ECO:0000269|PubMed:7474150"
FT   MUTAGEN         25
FT                   /note="S->T: No effect on polyprotein processing and viral
FT                   replication."
FT                   /evidence="ECO:0000269|PubMed:7474150"
FT   MUTAGEN         152
FT                   /note="P->G: No effect on RT or RNase H activities."
FT                   /evidence="ECO:0000269|PubMed:7544460"
FT   MUTAGEN         169
FT                   /note="P->G: 30% loss of RT activity."
FT                   /evidence="ECO:0000269|PubMed:7544460"
FT   MUTAGEN         193
FT                   /note="P->G: 40% loss of RT activity."
FT                   /evidence="ECO:0000269|PubMed:7544460"
FT   MUTAGEN         599
FT                   /note="D->A: 95% loss of RNase H activity."
FT                   /evidence="ECO:0000269|PubMed:7544460"
FT   MUTAGEN         672
FT                   /note="Y->F: 50% loss of RNase H activity."
FT                   /evidence="ECO:0000269|PubMed:7544460"
FT   STRAND          593..603
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   STRAND          613..621
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   STRAND          624..626
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   STRAND          629..639
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   HELIX           642..659
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   STRAND          660..662
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   STRAND          664..669
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   HELIX           671..678
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   HELIX           680..686
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   STRAND          693..695
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   HELIX           700..712
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   STRAND          717..720
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   STRAND          723..725
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   STRAND          727..729
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   HELIX           731..749
FT                   /evidence="ECO:0007744|PDB:2LSN"
FT   HELIX           760..767
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   STRAND          773..775
FT                   /evidence="ECO:0007744|PDB:3L2V"
FT   STRAND          777..779
FT                   /evidence="ECO:0007744|PDB:3L2R"
FT   STRAND          781..784
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   STRAND          787..792
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   STRAND          795..798
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   HELIX           802..804
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   HELIX           805..814
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   TURN            815..817
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   HELIX           820..828
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   HELIX           836..844
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   HELIX           848..853
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   STRAND          858..860
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   STRAND          874..881
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   STRAND          892..898
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   TURN            899..901
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   STRAND          904..912
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   HELIX           914..924
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   TURN            925..927
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   STRAND          931..935
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   HELIX           939..942
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   HELIX           944..953
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   STRAND          956..959
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   HELIX           965..968
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   HELIX           970..987
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   TURN            990..996
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   HELIX           997..1005
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   TURN            1010..1012
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   HELIX           1016..1021
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   STRAND          1023..1025
FT                   /evidence="ECO:0007744|PDB:2X6N"
FT   STRAND          1028..1030
FT                   /evidence="ECO:0007744|PDB:2X74"
FT   TURN            1033..1036
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   HELIX           1040..1054
FT                   /evidence="ECO:0007744|PDB:2X78"
FT   STRAND          1073..1077
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   STRAND          1092..1099
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   STRAND          1102..1106
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   STRAND          1108..1110
FT                   /evidence="ECO:0007744|PDB:4BE2"
FT   STRAND          1112..1116
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   HELIX           1117..1119
FT                   /evidence="ECO:0007744|PDB:3OYM"
FT   STRAND          1120..1122
FT                   /evidence="ECO:0007744|PDB:3OYM"
SQ   SEQUENCE   1143 AA;  129742 MW;  786E3203B06FFB3C CRC64;
     MNPLQLLQPL PAEIKGTKLL AHWDSGATIT CIPESFLEDE QPIKKTLIKT IHGEKQQNVY
     YVTFKVKGRK VEAEVIASPY EYILLSPTDV PWLTQQPLQL TILVPLQEYQ EKILSKTALP
     EDQKQQLKTL FVKYDNLWQH WENQVGHRKI RPHNIATGDY PPRPQKQYPI NPKAKPSIQI
     VIDDLLKQGV LTPQNSTMNT PVYPVPKPDG RWRMVLDYRE VNKTIPLTAA QNQHSAGILA
     TIVRQKYKTT LDLANGFWAH PITPESYWLT AFTWQGKQYC WTRLPQGFLN SPALFTADVV
     DLLKEIPNVQ VYVDDIYLSH DDPKEHVQQL EKVFQILLQA GYVVSLKKSE IGQKTVEFLG
     FNITKEGRGL TDTFKTKLLN ITPPKDLKQL QSILGLLNFA RNFIPNFAEL VQPLYNLIAS
     AKGKYIEWSE ENTKQLNMVI EALNTASNLE ERLPEQRLVI KVNTSPSAGY VRYYNETGKK
     PIMYLNYVFS KAELKFSMLE KLLTTMHKAL IKAMDLAMGQ EILVYSPIVS MTKIQKTPLP
     ERKALPIRWI TWMTYLEDPR IQFHYDKTLP ELKHIPDVYT SSQSPVKHPS QYEGVFYTDG
     SAIKSPDPTK SNNAGMGIVH ATYKPEYQVL NQWSIPLGNH TAQMAEIAAV EFACKKALKI
     PGPVLVITDS FYVAESANKE LPYWKSNGFV NNKKKPLKHI SKWKSIAECL SMKPDITIQH
     EKGISLQIPV FILKGNALAD KLATQGSYVV NCNTKKPNLD AELDQLLQGH YIKGYPKQYT
     YFLEDGKVKV SRPEGVKIIP PQSDRQKIVL QAHNLAHTGR EATLLKIANL YWWPNMRKDV
     VKQLGRCQQC LITNASNKAS GPILRPDRPQ KPFDKFFIDY IGPLPPSQGY LYVLVVVDGM
     TGFTWLYPTK APSTSATVKS LNVLTSIAIP KVIHSDQGAA FTSSTFAEWA KERGIHLEFS
     TPYHPQSGSK VERKNSDIKR LLTKLLVGRP TKWYDLLPVV QLALNNTYSP VLKYTPHQLL
     FGIDSNTPFA NQDTLDLTRE EELSLLQEIR TSLYHPSTPP ASSRSWSPVV GQLVQERVAR
     PASLRPRWHK PSTVLKVLNP RTVVILDHLG NNRTVSIDNL KPTSHQNGTT NDTATMDHLE
     KNE
//
